12 min
COVID-19 and Tocilizumab FOAMcast - An Emergency Medicine Podcast
-
- Medicine
Early studies of tocilizumab, a monoclonal antibody that binds interleukin-6 , were disappointing. However, the REMAP-CAP trial recently reported a benefit to tocilizumab in non-critically ill hospitalized patients with COVID-19. Now, from the RECOVERY trial (the trial that brought us dexamethasone), we have more good news for tocilizumab - which we cover in this podcast
Show notes: FOAMcast.org
Thanks for listening!
Lauren Westafer and Jeremy Faust
Early studies of tocilizumab, a monoclonal antibody that binds interleukin-6 , were disappointing. However, the REMAP-CAP trial recently reported a benefit to tocilizumab in non-critically ill hospitalized patients with COVID-19. Now, from the RECOVERY trial (the trial that brought us dexamethasone), we have more good news for tocilizumab - which we cover in this podcast
Show notes: FOAMcast.org
Thanks for listening!
Lauren Westafer and Jeremy Faust
12 min